• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Summit Therapeutics Inc.

    5/19/25 4:45:32 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SMMT alert in real time by email
    S-8 1 d934315ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 19, 2025

    Registration No. 333-   

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    SUMMIT THERAPEUTICS INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   37-1979717

    (State or Other Jurisdiction of

    Incorporation or Organization)

     

    (I.R.S. Employer

    Identification No.)

    601 Brickell Key Drive, Suite 1000

    Miami, FL

    (Address of Principal Executive Offices)

    2020 Stock Incentive Plan

    Summit Therapeutics Inc. Inducement Awards

    (Full Title of the Plans)

    Robert Duggan

    Co-Chief Executive Officer

    Summit Therapeutics Inc.

    601 Brickell Key Drive, Suite 1000

    Miami, FL 33131

    (305) 203-2034

    Mahkam Zanganeh

    Co-Chief Executive Officer

    Summit Therapeutics Inc.

    601 Brickell Key Drive, Suite 1000

    Miami, FL 33131

    (305) 203-2034

    (Name, Address and Telephone Number, Including Area Code, of Agent for Service)

     

     

    Copies to:

    Adam Finerman, Esq.

    Baker & Hostetler LLP

    45 Rockefeller Plaza

    New York, NY 10111

    Telephone: (212) 589-4233

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
         Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     
     


    EXPLANATORY NOTE

    Summit Therapeutics Inc. (the “Registrant”) is filing this registration statement on Form S-8 (the “Registration Statement”) with the Securities and Exchange Commission (the “Commission”) for the purpose of registering an aggregate of 10,400,000 shares of its common stock, par value $0.01 per share (the “Common Stock”), consisting of: (i) 6,400,000 additional shares of Common Stock that were added to the shares authorized for issuance under, and in accordance with, the Registrant’s Amended and Restated 2020 Stock Incentive Plan (the “2020 Plan”), effective January 1, 2025 (of which 3,061,572 shares are issuable upon the exercise of outstanding options granted under the 2020 Plan); and (ii) 4,000,000 shares of Common Stock reserved for future issuance as inducement to new employees in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Awards”) (of which 2,244,240 shares are issuable upon the exercise of outstanding inducement stock options granted by the Registrant as inducement to new employees in accordance with Nasdaq Listing Rule 5635(c)(4)). The Inducement Awards will be granted outside of the 2020 Plan, but pursuant to the terms of the 2020 Plan as if such Inducement Awards were granted under the 2020 Plan, pursuant to the “inducement” grant exception under Nasdaq Listing Rule 5635(c)(4) and have been approved by the Registrant’s Compensation Committee of the Board of Directors.

    The Registrant previously registered shares of Common Stock for issuance under the 2020 Plan under Registration Statements on Form S-8 filed with the Commission on October 5, 2020 (File No. 333-249313), April 6, 2022 (File No. 333-264163), and May 1, 2024 (File No. 333-279024). Pursuant to General Instruction E to Form S-8 this Registration Statement hereby incorporates by reference the contents of the Registration Statements referenced in the preceding sentence.


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information specified in Item 1 and Item 2 of Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act. The documents containing the information specified in Item 1 and Item 2 of Part I of Form S-8 will be delivered to the participants in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference.

    The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14, and 15(d) of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Securities and Exchange Commission (the “Commission”). The following documents, which have been filed with the Commission, are incorporated in this Registration Statement by reference:

     

      (a)

    The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on February 24, 2025;

     

      (b)

    The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December  31, 2024 from the Registrant’s Definitive Proxy Statement on Schedule 14A (other than information furnished rather than filed), filed with the Securities and Exchange Commission on April 29, 2025;

     

      (c)

    The Registrant’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, filed with the Commission on May 1, 2025;

     

      (d)

    The Registrant’s Current Reports on Form 8-K filed on January  24, 2025, April  23, 2025 and April 25, 2025; and

     

      (e)

    The description of the Registrant’s Common Stock contained on the Registrant’s Current Report on Form 8-K dated September 18, 2020, including any amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 4.

    Description of Securities

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel

    Not applicable.

     

    Item 6.

    Indemnification of Directors and Officers

    Section 102 of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. The Registrant’s certificate of incorporation provides that none of its directors shall be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duty as director, notwithstanding any provision of law imposing such liability, except to the extent that the Delaware General Corporation Law prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.


    Section 145 of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

    The Registrant’s certificate of incorporation provides that the Registrant will indemnify each person who was or is a party or threatened to be made a party to or is involved in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Registrant) by reason of the fact that he or she is or was a director or officer of the Registrant, or is or was serving at the Registrant’s request as a director or officer of another corporation, partnership, joint venture, trust or other enterprise to the fullest extent permitted by the Delaware General Corporation Law. The Registrant’s certificate of incorporation provides that any reasonable, documented, out-pocket expenses must be advanced to these indemnitees under certain circumstances.

    The indemnification provisions contained in the Registrant’s certificate of incorporation are not exclusive. In addition, the Registrant has entered into indemnification agreements with each of its directors and executive officers. Each indemnification agreement provides that the Registrant will indemnify the director or executive officer to the fullest extent permitted by law for claims arising in his or her capacity as a director or executive officer, provided that he or she acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the Registrant’s best interests and, with respect to any criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful. In the event that the Registrant does not assume the defense of a claim against a director or executive officer, the Registrant is required to advance his or her expenses in connection with his or her defense, provided that he or she undertakes to repay all amounts advanced if it is ultimately determined that he or she is not entitled to be indemnified by the Registrant.

    In addition, the Registrant maintains standard policies of insurance under which coverage is provided to the Registrant’s directors and officers against losses arising from claims made by reason of breach of duty or other wrongful act, and to the Registrant with respect to payments which may be made by the Registrant to such directors and officers pursuant to the above indemnification provisions or otherwise as a matter of law.

     

    Item 7.

    Exemption From Registration Claimed

    Not applicable.


    Item 8.

    Exhibits.

     

    Exhibit
    Number
      

    Exhibit Description

    4.1    Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the registrant’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)
    4.2    Amendment to Restated Certificate of Incorporation of Summit Therapeutics Inc., as filed with the Delaware Secretary of State on July  27, 2022 (incorporated by reference to Exhibit 3.1 of Form 8-K filed by the Registrant on July 29, 2022, File No. 001-36866)
    4.3    Amendment No. 2 to Restated Certificate of Incorporation, dated January  19, 2023 (incorporated by reference to Exhibit 5.1 of Form 8-K filed by the Registrant on January 20, 2023, File No. 001-36866)
    4.4    Amended and Restated Bylaws of the registrant (incorporated by reference to Exhibit 3.2 to the registrant’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 18, 2020)
    5.1    Opinion of Baker & Hostetler LLP
    23.1    Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm for the registrant
    23.2    Consent of Baker & Hostetler LLP (included in Exhibit 5.1)
    24.1    Power of Attorney (included on signature page)
    99.1    Amended and Restated 2020 Stock Incentive Plan, dated October  12, 2023 (incorporated by reference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 (File No.  333-279024), filed with the Securities and Exchange Commission on May 1, 2024)
    99.2    Form of Option Award under 2020 Stock Incentive Plan
    99.3    Form of Restricted Stock Unit Agreement under 2020 Stock Incentive Plan (incorporated by reference to Exhibit 10.29 to the Company’s Current Report on Form 8-K (File No. 001-36866), filed with the Securities and Exchange Commission on September 29, 2020)
    99.4    Form of Stock Option Inducement Grant Notice and Option Agreement Inducement Grant
    107    Filing Fee Table

     

    Item 9.

    Undertakings

    (a) The undersigned Registrant hereby undertakes:

     

      (1)

    To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

      (i)

    to include any prospectus required by Section 10(a)(3) of the Securities Act;

     

      (ii)

    to reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from


      the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee Tables” or “Calculation of Registration Fee” table, as applicable, in the effective registration statement; and

     

      (iii)

    to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the registration statement;

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the Registration Statement is on Form S-8, and the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

      (2)

    That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

      (3)

    To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, on May 19, 2025.

     

    SUMMIT THERAPEUTICS INC.
    By:  

    /s/ Robert W. Duggan

      Robert W. Duggan
      Co-Chief Executive Officer and Executive Chairman (Principal Executive Officer)
    By:  

    /s/ Mahkam Zanganeh

      Dr. Mahkam Zanganeh
      Co-Chief Executive Officer, President and Director (Principal Executive Officer)

    SIGNATURES AND POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Robert W. Duggan, Mahkam Zanganeh and Manmeet Soni, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities held on the dates indicated.

     

    Name

      

    Position

      

    Date

    /s/ Robert W. Duggan

    Robert W. Duggan

      

    Co-Chief Executive Officer and Executive Chairman

    (Principal Executive Officer)

       May 19, 2025

    /s/ Mahkam Zanganeh

    Dr. Mahkam Zanganeh

      

    Co-Chief Executive Officer, President and Director

    (Principal Executive Officer)

       May 19, 2025

    /s/ Manmeet S. Soni

    Manmeet S. Soni

      

    Chief Operating Officer, Chief Financial Officer and Director

    (Principal Financial Officer)

       May 19, 2025

    /s/ Bhaskar Anand

    Bhaskar Anand

      

    Head of Finance and Chief Accounting Officer

    (Principal Accounting Officer)

       May 19, 2025

    /s/ Robert F. Booth

    Dr. Robert F. Booth

       Director    May 19, 2025

    /s/ Alessandra Cesano

    Alessandra Cesano

       Director    May 19, 2025


    /s/ Kenneth Clark

    Kenneth Clark

       Director    May 19, 2025

    /s/ Jeff Huber

    Jeff Huber

       Director    May 19, 2025

    /s/ Mostafa Ronaghi

    Mostafa Ronaghi

       Director    May 19, 2025

    /s/ Yu Xia

    Dr. Yu Xia

       Director    May 19, 2025
    Get the next $SMMT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SMMT

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Underperform
    Leerink Partners
    3/26/2025$23.00 → $35.00Neutral → Buy
    Citigroup
    3/21/2025Overweight
    Cantor Fitzgerald
    3/12/2025$30.00Outperform
    Evercore ISI
    2/28/2025$42.00Buy
    Goldman
    1/8/2025$35.00Buy
    Truist
    12/11/2024$30.00Overweight
    Wells Fargo
    12/6/2024$31.00Buy
    Jefferies
    More analyst ratings

    $SMMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Leerink Partners initiated coverage on Summit Therapeutics with a new price target

      Leerink Partners initiated coverage of Summit Therapeutics with a rating of Underperform and set a new price target of $12.00

      6/11/25 7:54:51 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Summit Therapeutics from Neutral to Buy and set a new price target of $35.00 from $23.00 previously

      3/26/25 7:47:33 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Summit Therapeutics

      Cantor Fitzgerald initiated coverage of Summit Therapeutics with a rating of Overweight

      3/21/25 8:11:46 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 71,275 shares of common stock. Awards were made to seven new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Committee. The inducement awards were granted on June 2, 2025. The options have a ten (10) year term and an exercise price of $17.72 per share, the closing price per share of the Company's common stock as reported by Nasdaq on June

      6/6/25 4:44:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at the 46th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 9, 2025, at 1:20 PM ET. Members of the Summit management team will participate in a fireside chat presentation providing a corporate overview and update on the progress of our organization, including the development of our innovative investigational bispecific antibody, ivonescimab. The presentation will be available live from our website: www.smmttx.com. An archived version of the presentation will be available on our website following the presentation. About Summ

      6/5/25 8:00:00 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer after EGFR TKI Therapy in Global Study

      Consistent Results Noted between Single Region HARMONi-A and Multiregional HARMONi Studies; Favorable Trends in Sub-Populations from North America and China for Both Primary Endpoints Were Observed Ivonescimab in Combination with Chemotherapy Reduces the Risk of Disease Progression or Death by 48% Compared to Chemotherapy Alone; Positive Overall Survival Trend Observed with Hazard Ratio of 0.79 HARMONi Represents the First Phase III Trial to Evaluate Ivonescimab in a Multiregional Setting Summit to Determine Timing of US BLA Filing Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced topline results from the Phase III clinical trial, HARMONi, the

      5/30/25 6:00:00 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Co-Chief Executive Officer Zanganeh Mahkam exercised 74,545 shares at a strike of $2.64 (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      6/2/25 5:01:16 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Co-Chief Executive Officer Duggan Robert W exercised 74,545 shares at a strike of $2.64, increasing direct ownership by 0.01% to 555,754,696 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      6/2/25 4:55:56 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Accounting Officer Anand Bhaskar

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      5/1/25 6:17:22 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Zanganeh Mahkam bought $411,094 worth of shares (110,321 units at $3.73), increasing direct ownership by 5% to 520,814 units (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:28:30 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dhingra Ankur bought $375,000 worth of shares (100,000 units at $3.75) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      3/27/24 8:27:03 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Zanganeh Mahkam exercised 805,495 in-the-money shares at a strike of $1.49 and bought $10,350 worth of shares (5,000 units at $2.07) (SEC Form 4)

      4 - Summit Therapeutics Inc. (0001599298) (Issuer)

      12/13/23 5:11:56 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    SEC Filings

    See more
    • Summit Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      6/20/25 5:07:50 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      6/17/25 4:13:55 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Summit Therapeutics Inc. (0001599298) (Filer)

      5/30/25 4:17:49 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Financials

    Live finance-specific insights

    See more
    • Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2025

      Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in First-Line Treatment of Patients with Advanced Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China Enrollment Continues in Global Phase III Trial HARMONi-3 in First-Line Treatment of Patients with Metastatic NSCLC Ivonescimab Receives Approval in China as Monotherapy for First-Line Treatment for Advanced NSCLC in Tumors with Positive PD-L1 Expression: Interim Overall Survival HR = 0.777 in China for HARMONi-2 Study Conducted by Akeso Enrollment Has Begun in HARMONi-7 Global Phase III Trial in First-Line PD-L1 High, Metastatic

      5/1/25 4:09:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics to Host First Quarter 2025 Financial Results & Operational Progress Call on May 1, 2025

      Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its first quarter 2025 financial results and provide an operational update for the Company on Thursday, May 1, 2025, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and

      4/24/25 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Twelve Months Ended December 31, 2024

      Clinical Trial Collaboration with Pfizer Evaluating Ivonescimab in Combination with Several Vedotin ADCs in Unique Solid Tumor Settings; Clinical Trials Expected to Start Mid-2025 Enrollment Completed for Global, Multi-Regional Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Top-Line Data Expected Mid-2025; Received Fast Track Designation from FDA HARMONi-3 Global Phase III Trial Expanded to Include Patients with Squamous and Non-Squamous Histologies Initial Trial Sites Activated for Global Phase III HARMONi-7 Trial in 1L PD-L1 High, Advanced NSCLC Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an updat

      2/24/25 6:05:00 AM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SMMT
    Leadership Updates

    Live Leadership Updates

    See more
    • Robert LaCaze, Innovative Growth-Driver in Oncology, Joins Summit Therapeutics as Chief Commercial Officer

      Mr. LaCaze Brings Over 35 Years of Executive Leadership Experience in the Biopharmaceutical Industry Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, "Robert's extensive experience and proven track record in the oncology space make him an exceptional addition to our team. His leadership will be instrumental as we seek to bring ivonescimab to patients in need. We are truly excited to have

      3/17/25 4:24:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Jeff Huber has been appointed to its Board of Directors, effective immediately. "It is an honor to add Jeff Huber to our excellent, diverse group of board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Jeff's executive leadership experience in healthcare and technology and his countless accomplishments evidence his ability to translate what's possible into transformational success. As we seek to change the standard of care for solid tumors based on the potential of ivonescimab, we are thrilled to supplement our outstanding leadership team with a board member

      6/27/24 4:15:00 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors

      Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, effective immediately. "We are excited to add Dr. Ronaghi to complement our excellent group of current board members," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "Mostafa has valuable experience in translating innovative concepts in genomics and sequencing that ultimately lead to advancements in patient care through his work at Illumina, Grail, and his continuing ventures. As we intend to maximize the potential of ivonescimab, we are excited to add the acumen and expertise that Mostafa can bring to

      4/11/24 4:30:00 PM ET
      $ILMN
      $SMMT
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $SMMT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Summit Therapeutics Inc.

      SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

      9/13/24 5:54:25 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

      SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

      3/13/23 4:51:59 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Summit Therapeutics Inc. (Amendment)

      SC 13D/A - Summit Therapeutics Inc. (0001599298) (Subject)

      2/16/23 4:01:07 PM ET
      $SMMT
      Biotechnology: Pharmaceutical Preparations
      Health Care